



Clinical trial results:

A Multi-Center Randomized Double Blind Vehicle-Controlled, Phase 2 Study of the safety and efficacy of Benzoyl Peroxide/Clindamycin Gel and Tazarotene Cream when used in combination in the treatment of Acne Vulgaris

Summary

| | |
|--------------------------|----------------|
| EudraCT number | 2015-004900-44 |
| Trial protocol | Outside EU/EEA |
| Global end of trial date | 02 March 2009 |

Results information

| | |
|--------------------------------|-----------------|
| Result version number | v1 |
| This version publication date | 22 January 2017 |
| First version publication date | 22 January 2017 |

Trial information

Trial identification

| | |
|-----------------------|--------|
| Sponsor protocol code | 114570 |
|-----------------------|--------|

Additional study identifiers

| | |
|------------------------------------|---|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | - |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|--|
| Sponsor organisation name | GlaxoSmithKline |
| Sponsor organisation address | 980 Great West Road, Brentford, Middlesex, United Kingdom, |
| Public contact | GSK Response Center, GlaxoSmithKline, 1 866-435-7343, |
| Scientific contact | GSK Response Center, GlaxoSmithKline, 1 866-435-7343, |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|---------------|
| Analysis stage | Final |
| Date of interim/final analysis | 02 July 2009 |
| Is this the analysis of the primary completion data? | No |
| Global end of trial reached? | Yes |
| Global end of trial date | 02 March 2009 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

To evaluate the safety and efficacy of Duac and Tazorac when applied simultaneously to subjects with facial acne vulgaris.

Protection of trial subjects:

Not applicable

Background therapy: -

Evidence for comparator: -

| | |
|---|--------------|
| Actual start date of recruitment | 15 June 2008 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|--------------------|
| Country: Number of subjects enrolled | United States: 587 |
| Worldwide total number of subjects | 587 |
| EEA total number of subjects | 0 |

Notes:

Subjects enrolled per age group

| | |
|---|-----|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 301 |
| Adults (18-64 years) | 286 |
| From 65 to 84 years | 0 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details:

In this multi-center, double-blind, vehicle controlled study, participants were assigned to one of the six treatment groups in a 2:2:2:2:2:1 ratio for 12 weeks.

Pre-assignment

Screening details:

Participants with facial acne vulgaris, 12 to 45 years of age were enrolled in this study. A total of 596 participants were randomized and 587 participants received study product.

Period 1

| | |
|------------------------------|---|
| Period 1 title | Overall Study (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Subject, Investigator, Monitor, Carer, Assessor |

Arms

| | |
|------------------------------|---|
| Are arms mutually exclusive? | Yes |
| Arm title | Benzoyl peroxide/Clindamycin + Tazarotene |

Arm description:

Participants applied the study product (Benzoyl peroxide/Clindamycin + Tazarotene) to the face once daily in the evening up to 12 weeks. Two actuations of test product (approximately 0.6 grams [g] of the combined product in an approximate 1:1 ratio) were dispensed into the participant's palm and mixed. A thin film was then applied to the entire face.

| | |
|--|------------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Benzoyl peroxide/Clindamycin |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Gel |
| Routes of administration | Topical use |

Dosage and administration details:

Benzoyl peroxide/Clindamycin contained 1% clindamycin phosphate and 5% BPO in a gel vehicle. It was applied once daily in the evening.

| | |
|--|-------------|
| Investigational medicinal product name | Tazarotene |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Cream |
| Routes of administration | Topical use |

Dosage and administration details:

Tazarotene, which contained 0.1 % tazarotene in a cream vehicle. It was applied once daily in the evening.

| | |
|------------------|--|
| Arm title | Benzoyl peroxide/Clindamycin + vehicle cream |
|------------------|--|

Arm description:

Participants applied the study product (Benzoyl peroxide/Clindamycin + vehicle cream with identical ingredients as Tazarotene) to the face once daily in the evening up to 12 weeks. Two actuations of test product (approximately 0.6 g of the combined product in an approximate 1:1 ratio) were dispensed into the participant's palm and mixed. A thin film was then applied to the entire face.

| | |
|----------|-------------------|
| Arm type | Active comparator |
|----------|-------------------|

| | |
|--|---------------|
| Investigational medicinal product name | Vehicle cream |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Cream |
| Routes of administration | Topical use |

Dosage and administration details:

Vehicle cream contained identical ingredients as Tazarotene but without the active ingredient. It was applied once daily in the evening.

| | |
|--|------------------------------|
| Investigational medicinal product name | Benzoyl peroxide/Clindamycin |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Gel |
| Routes of administration | Topical use |

Dosage and administration details:

Benzoyl peroxide/Clindamycin contained 1% clindamycin phosphate and 5% BPO in a gel vehicle. It was applied once daily in the evening.

| | |
|------------------|-----------------------------------|
| Arm title | Benzoyl peroxide gel + Tazarotene |
|------------------|-----------------------------------|

Arm description:

Participants applied the study product (Benzoyl peroxide gel + Tazarotene) to the face once daily in the evening up to 12 weeks. Two actuations of test product (approximately 0.6 g of the combined product in an approximate 1:1 ratio) were dispensed into the participant's palm and mixed. A thin film was then applied to the entire face.

| | |
|--|-------------------|
| Arm type | Active comparator |
| Investigational medicinal product name | Tazarotene |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Cream |
| Routes of administration | Topical use |

Dosage and administration details:

Tazarotene, which contained 0.1 % tazarotene in a cream vehicle. It was applied once daily in the evening.

| | |
|--|------------------|
| Investigational medicinal product name | Benzoyl Peroxide |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Gel |
| Routes of administration | Topical use |

Dosage and administration details:

Benzoyl Peroxide gel contained identical ingredients as Benzoyl peroxide/Clindamycin but without the clindamycin. It was applied once daily in the evening.

| | |
|------------------|------------------------------|
| Arm title | Clindamycin gel + Tazarotene |
|------------------|------------------------------|

Arm description:

Participants applied the study product (Clindamycin gel + Tazarotene) to the face once daily in the evening up to 12 weeks. Two actuations of test product (approximately 0.6 g of the combined product in an approximate 1:1 ratio) were dispensed into the participant's palm and mixed. A thin film was then applied to the entire face.

| | |
|--|-------------------|
| Arm type | Active comparator |
| Investigational medicinal product name | Clindamycin gel |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Gel |
| Routes of administration | Topical use |

Dosage and administration details:

Clindamycin gel contained identical ingredients as Benzoyl peroxide/Clindamycin but without the Benzoyl Peroxide. It was applied once daily in the evening.

| | |
|--|-------------|
| Investigational medicinal product name | Tazarotene |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Cream |
| Routes of administration | Topical use |

Dosage and administration details:

Tazarotene, which contained 0.1 % tazarotene in a cream vehicle. It was applied once daily in the evening.

| | |
|------------------|--------------------------|
| Arm title | Vehicle gel + Tazarotene |
|------------------|--------------------------|

Arm description:

Participants applied the study product (Vehicle gel with identical ingredients as Benzoyl peroxide/Clindamycin + Tazarotene) to the face once daily in the evening up to 12 weeks. Two actuations of test product (approximately 0.6 g of the combined product in an approximate 1:1 ratio) were dispensed into the participant's palm and mixed. A thin film was then applied to the entire face.

| | |
|--|-------------------|
| Arm type | Active comparator |
| Investigational medicinal product name | Vehicle gel |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Gel |
| Routes of administration | Topical use |

Dosage and administration details:

Vehicle gel contained identical ingredients as Benzoyl peroxide/Clindamycin but without the active ingredients. It was applied once daily in the evening.

| | |
|--|-------------|
| Investigational medicinal product name | Tazarotene |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Cream |
| Routes of administration | Topical use |

Dosage and administration details:

Tazarotene, which contained 0.1 % tazarotene in a cream vehicle. It was applied once daily in the evening.

| | |
|------------------|-----------------------------|
| Arm title | Vehicle gel + vehicle cream |
|------------------|-----------------------------|

Arm description:

Participants applied the study product (Vehicle gel with identical ingredients as Benzoyl peroxide/Clindamycin+ vehicle cream with identical ingredients as Tazarotene) to the face once daily in the evening up to 12 weeks. Two actuations of test product (approximately 0.6 g of the combined product in an approximate 1:1 ratio) were dispensed into the participant's palm and mixed. A thin film was then applied to the entire face.

| | |
|--|-------------|
| Arm type | Placebo |
| Investigational medicinal product name | Vehicle gel |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Gel |
| Routes of administration | Topical use |

Dosage and administration details:

Vehicle gel contained identical ingredients as Benzoyl peroxide/Clindamycin but without the active ingredients. It was applied once daily in the evening.

| | |
|--|---------------|
| Investigational medicinal product name | Vehicle cream |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Cream |
| Routes of administration | Topical use |

Dosage and administration details:

Vehicle cream contained identical ingredients as Tazarotene but without the active ingredient. It was applied once daily in the evening.

| Number of subjects in period 1 | Benzoyl peroxide/Clindamycin + Tazarotene | Benzoyl peroxide/Clindamycin + vehicle cream | Benzoyl peroxide gel + Tazarotene |
|---------------------------------------|---|--|-----------------------------------|
| Started | 106 | 105 | 107 |
| Completed | 85 | 90 | 92 |
| Not completed | 21 | 15 | 15 |
| Consent withdrawn by subject | 6 | 1 | 5 |
| Adverse event, non-fatal | 2 | - | 2 |
| Non-compliance with Study Treatment | 1 | 1 | 2 |
| Lost to follow-up | 5 | 7 | 5 |
| Lack of efficacy | 1 | 3 | - |
| Protocol deviation | 6 | 3 | 1 |

| Number of subjects in period 1 | Clindamycin gel + Tazarotene | Vehicle gel + Tazarotene | Vehicle gel + vehicle cream |
|---------------------------------------|------------------------------|--------------------------|-----------------------------|
| Started | 108 | 106 | 55 |
| Completed | 99 | 87 | 47 |
| Not completed | 9 | 19 | 8 |
| Consent withdrawn by subject | 1 | 5 | 7 |
| Adverse event, non-fatal | 2 | 3 | 1 |
| Non-compliance with Study Treatment | - | 1 | - |
| Lost to follow-up | 5 | 7 | - |
| Lack of efficacy | - | 1 | - |
| Protocol deviation | 1 | 2 | - |

Baseline characteristics

Reporting groups

| | |
|-----------------------|---|
| Reporting group title | Benzoyl peroxide/Clindamycin + Tazarotene |
|-----------------------|---|

Reporting group description:

Participants applied the study product (Benzoyl peroxide/Clindamycin + Tazarotene) to the face once daily in the evening up to 12 weeks. Two actuations of test product (approximately 0.6 grams [g] of the combined product in an approximate 1:1 ratio) were dispensed into the participant's palm and mixed. A thin film was then applied to the entire face.

| | |
|-----------------------|--|
| Reporting group title | Benzoyl peroxide/Clindamycin + vehicle cream |
|-----------------------|--|

Reporting group description:

Participants applied the study product (Benzoyl peroxide/Clindamycin + vehicle cream with identical ingredients as Tazarotene) to the face once daily in the evening up to 12 weeks. Two actuations of test product (approximately 0.6 g of the combined product in an approximate 1:1 ratio) were dispensed into the participant's palm and mixed. A thin film was then applied to the entire face.

| | |
|-----------------------|-----------------------------------|
| Reporting group title | Benzoyl peroxide gel + Tazarotene |
|-----------------------|-----------------------------------|

Reporting group description:

Participants applied the study product (Benzoyl peroxide gel + Tazarotene) to the face once daily in the evening up to 12 weeks. Two actuations of test product (approximately 0.6 g of the combined product in an approximate 1:1 ratio) were dispensed into the participant's palm and mixed. A thin film was then applied to the entire face.

| | |
|-----------------------|------------------------------|
| Reporting group title | Clindamycin gel + Tazarotene |
|-----------------------|------------------------------|

Reporting group description:

Participants applied the study product (Clindamycin gel + Tazarotene) to the face once daily in the evening up to 12 weeks. Two actuations of test product (approximately 0.6 g of the combined product in an approximate 1:1 ratio) were dispensed into the participant's palm and mixed. A thin film was then applied to the entire face.

| | |
|-----------------------|--------------------------|
| Reporting group title | Vehicle gel + Tazarotene |
|-----------------------|--------------------------|

Reporting group description:

Participants applied the study product (Vehicle gel with identical ingredients as Benzoyl peroxide/Clindamycin + Tazarotene) to the face once daily in the evening up to 12 weeks. Two actuations of test product (approximately 0.6 g of the combined product in an approximate 1:1 ratio) were dispensed into the participant's palm and mixed. A thin film was then applied to the entire face.

| | |
|-----------------------|-----------------------------|
| Reporting group title | Vehicle gel + vehicle cream |
|-----------------------|-----------------------------|

Reporting group description:

Participants applied the study product (Vehicle gel with identical ingredients as Benzoyl peroxide/Clindamycin+ vehicle cream with identical ingredients as Tazarotene) to the face once daily in the evening up to 12 weeks. Two actuations of test product (approximately 0.6 g of the combined product in an approximate 1:1 ratio) were dispensed into the participant's palm and mixed. A thin film was then applied to the entire face.

| Reporting group values | Benzoyl peroxide/Clindamycin + Tazarotene | Benzoyl peroxide/Clindamycin + vehicle cream | Benzoyl peroxide gel + Tazarotene |
|--|---|--|-----------------------------------|
| Number of subjects | 106 | 105 | 107 |
| Age categorical Units: Subjects | | | |
| Age continuous | | | |
| Age continuous description Units: years | | | |
| arithmetic mean | 19.7 | 19.7 | 20.2 |
| standard deviation | ± 6.2 | ± 6.9 | ± 7.3 |

| | | | |
|---|----|----|----|
| Gender categorical | | | |
| Gender categorical description | | | |
| Units: Subjects | | | |
| Female | 58 | 56 | 60 |
| Male | 48 | 49 | 47 |
| Race/Ethnicity, Customized | | | |
| Units: Subjects | | | |
| American Indian or Alaska Native | 1 | 0 | 0 |
| Asian | 8 | 14 | 5 |
| Black | 23 | 16 | 24 |
| Multiracial | 10 | 11 | 9 |
| Native Hawaiian or Other Pacific Islander | 1 | 1 | 1 |
| White | 63 | 63 | 68 |

| | | | |
|-------------------------------|------------------------------|--------------------------|-----------------------------|
| Reporting group values | Clindamycin gel + Tazarotene | Vehicle gel + Tazarotene | Vehicle gel + vehicle cream |
| Number of subjects | 108 | 106 | 55 |
| Age categorical | | | |
| Units: Subjects | | | |

| | | | |
|---|-------|-------|-------|
| Age continuous | | | |
| Age continuous description | | | |
| Units: years | | | |
| arithmetic mean | 19.2 | 21.7 | 19.8 |
| standard deviation | ± 6.2 | ± 8.4 | ± 6.6 |
| Gender categorical | | | |
| Gender categorical description | | | |
| Units: Subjects | | | |
| Female | 60 | 65 | 35 |
| Male | 48 | 41 | 20 |
| Race/Ethnicity, Customized | | | |
| Units: Subjects | | | |
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 6 | 9 | 5 |
| Black | 15 | 14 | 8 |
| Multiracial | 8 | 8 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 |
| White | 79 | 74 | 37 |

| | | | |
|-------------------------------|-------|--|--|
| Reporting group values | Total | | |
| Number of subjects | 587 | | |
| Age categorical | | | |
| Units: Subjects | | | |

| | | | |
|----------------------------|--|--|--|
| Age continuous | | | |
| Age continuous description | | | |
| Units: years | | | |
| arithmetic mean | | | |

| | | | |
|--------------------|---|--|--|
| standard deviation | - | | |
|--------------------|---|--|--|

| | | | |
|---|-----|--|--|
| Gender categorical | | | |
| Gender categorical description | | | |
| Units: Subjects | | | |
| Female | 334 | | |
| Male | 253 | | |
| Race/Ethnicity, Customized | | | |
| Units: Subjects | | | |
| American Indian or Alaska Native | 1 | | |
| Asian | 47 | | |
| Black | 100 | | |
| Multiracial | 51 | | |
| Native Hawaiian or Other Pacific Islander | 4 | | |
| White | 384 | | |

End points

End points reporting groups

| | |
|-----------------------|---|
| Reporting group title | Benzoyl peroxide/Clindamycin + Tazarotene |
|-----------------------|---|

Reporting group description:

Participants applied the study product (Benzoyl peroxide/Clindamycin + Tazarotene) to the face once daily in the evening up to 12 weeks. Two actuations of test product (approximately 0.6 grams [g] of the combined product in an approximate 1:1 ratio) were dispensed into the participant's palm and mixed. A thin film was then applied to the entire face.

| | |
|-----------------------|--|
| Reporting group title | Benzoyl peroxide/Clindamycin + vehicle cream |
|-----------------------|--|

Reporting group description:

Participants applied the study product (Benzoyl peroxide/Clindamycin + vehicle cream with identical ingredients as Tazarotene) to the face once daily in the evening up to 12 weeks. Two actuations of test product (approximately 0.6 g of the combined product in an approximate 1:1 ratio) were dispensed into the participant's palm and mixed. A thin film was then applied to the entire face.

| | |
|-----------------------|-----------------------------------|
| Reporting group title | Benzoyl peroxide gel + Tazarotene |
|-----------------------|-----------------------------------|

Reporting group description:

Participants applied the study product (Benzoyl peroxide gel + Tazarotene) to the face once daily in the evening up to 12 weeks. Two actuations of test product (approximately 0.6 g of the combined product in an approximate 1:1 ratio) were dispensed into the participant's palm and mixed. A thin film was then applied to the entire face.

| | |
|-----------------------|------------------------------|
| Reporting group title | Clindamycin gel + Tazarotene |
|-----------------------|------------------------------|

Reporting group description:

Participants applied the study product (Clindamycin gel + Tazarotene) to the face once daily in the evening up to 12 weeks. Two actuations of test product (approximately 0.6 g of the combined product in an approximate 1:1 ratio) were dispensed into the participant's palm and mixed. A thin film was then applied to the entire face.

| | |
|-----------------------|--------------------------|
| Reporting group title | Vehicle gel + Tazarotene |
|-----------------------|--------------------------|

Reporting group description:

Participants applied the study product (Vehicle gel with identical ingredients as Benzoyl peroxide/Clindamycin + Tazarotene) to the face once daily in the evening up to 12 weeks. Two actuations of test product (approximately 0.6 g of the combined product in an approximate 1:1 ratio) were dispensed into the participant's palm and mixed. A thin film was then applied to the entire face.

| | |
|-----------------------|-----------------------------|
| Reporting group title | Vehicle gel + vehicle cream |
|-----------------------|-----------------------------|

Reporting group description:

Participants applied the study product (Vehicle gel with identical ingredients as Benzoyl peroxide/Clindamycin+ vehicle cream with identical ingredients as Tazarotene) to the face once daily in the evening up to 12 weeks. Two actuations of test product (approximately 0.6 g of the combined product in an approximate 1:1 ratio) were dispensed into the participant's palm and mixed. A thin film was then applied to the entire face.

| | |
|----------------------------|---|
| Subject analysis set title | Benzoyl peroxide/Clindamycin + Tazarotene |
|----------------------------|---|

| | |
|---------------------------|--------------------|
| Subject analysis set type | Intention-to-treat |
|---------------------------|--------------------|

Subject analysis set description:

Participants applied the study product (Benzoyl peroxide/Clindamycin + Tazarotene) to the face once daily in the evening up to 12 weeks. Two actuations of test product (approximately 0.6 grams [g] of the combined product in an approximate 1:1 ratio) were dispensed into the participant's palm and mixed. A thin film was then applied to the entire face.

| | |
|----------------------------|--|
| Subject analysis set title | Benzoyl peroxide/Clindamycin + vehicle cream |
|----------------------------|--|

| | |
|---------------------------|--------------------|
| Subject analysis set type | Intention-to-treat |
|---------------------------|--------------------|

Subject analysis set description:

Participants applied the study product (Benzoyl peroxide/Clindamycin + vehicle cream with identical ingredients as Tazarotene) to the face once daily in the evening up to 12 weeks. Two actuations of test product (approximately 0.6 g of the combined product in an approximate 1:1 ratio) were dispensed into the participant's palm and mixed. A thin film was then applied to the entire face.

| | |
|----------------------------|------------------------------------|
| Subject analysis set title | Benzoyl peroxide gel + Tazarotene. |
|----------------------------|------------------------------------|

| | |
|---------------------------|--------------------|
| Subject analysis set type | Intention-to-treat |
|---------------------------|--------------------|

Subject analysis set description:

Participants applied the study product (Benzoyl peroxide gel + Tazarotene) to the face once daily in the

evening up to 12 weeks. Two actuations of test product (approximately 0.6 g of the combined product in an approximate 1:1 ratio) were dispensed into the participant's palm and mixed. A thin film was then applied to the entire face.

| | |
|----------------------------|-------------------------------|
| Subject analysis set title | Clindamycin gel + Tazarotene. |
| Subject analysis set type | Intention-to-treat |

Subject analysis set description:

Participants applied the study product (Clindamycin gel + Tazarotene) to the face once daily in the evening up to 12 weeks. Two actuations of test product (approximately 0.6 g of the combined product in an approximate 1:1 ratio) were dispensed into the participant's palm and mixed. A thin film was then applied to the entire face.

| | |
|----------------------------|---------------------------|
| Subject analysis set title | Vehicle gel + Tazarotene. |
| Subject analysis set type | Intention-to-treat |

Subject analysis set description:

Participants applied the study product (Vehicle gel with identical ingredients as Benzoyl peroxide/Clindamycin + Tazarotene) to the face once daily in the evening up to 12 weeks. Two actuations of test product (approximately 0.6 g of the combined product in an approximate 1:1 ratio) were dispensed into the participant's palm and mixed. A thin film was then applied to the entire face.

| | |
|----------------------------|------------------------------|
| Subject analysis set title | Vehicle gel + vehicle cream. |
| Subject analysis set type | Intention-to-treat |

Subject analysis set description:

Participants applied the study product (Vehicle gel with identical ingredients as Benzoyl peroxide/Clindamycin+ vehicle cream with identical ingredients as Tazarotene) to the face once daily in the evening up to 12 weeks. Two actuations of test product (approximately 0.6 g of the combined product in an approximate 1:1 ratio) were dispensed into the participant's palm and mixed. A thin film was then applied to the entire face.

Primary: Absolute change in lesion counts (total, inflammatory, and non-inflammatory) from Baseline to Week 12

| | |
|-----------------|---|
| End point title | Absolute change in lesion counts (total, inflammatory, and non-inflammatory) from Baseline to Week 12 |
|-----------------|---|

End point description:

The investigator or designee took count of inflammatory lesions (papules, pustules, nodules and cysts [only post-Baseline]) (ILC), noninflammatory lesions (open and closed comedones) (NILC) and total lesions (TLC) at Baseline, Weeks 2, 4, 8, and 12. Lesion counts were confined to the face. Each of 3 lesion counts (total, inflammatory and non-inflammatory) was analyzed using an analysis of covariance (ANCOVA) model with terms for treatment, center, Baseline value and treatment-by-center interaction. If the interaction was not significant at 0.1 level, this interaction was excluded in ANCOVA model. Day 1 (Visit 1) was defined as Baseline. Only participants available at specified timepoints were analyzed (represented by n=X in the category titles).

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Baseline and up to Week 12

| End point values | Benzoyl peroxide/Clindamycin + Tazarotene | Benzoyl peroxide/Clindamycin + vehicle cream | Benzoyl peroxide gel + Tazarotene | Clindamycin gel + Tazarotene |
|--------------------------------------|---|--|-----------------------------------|------------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 106 ^[1] | 105 ^[2] | 107 ^[3] | 107 ^[4] |
| Units: Lesion count | | | | |
| arithmetic mean (standard deviation) | | | | |
| ILC, n=101, 103, 105, 105, 104, 52 | -16.8 (± 14.35) | -18.1 (± 14.45) | -18.9 (± 12.84) | -18.8 (± 11.49) |
| NILC, n=101, 103, 105, 105, 104, 52 | -33 (± 23.94) | -24.9 (± 33.41) | -37.1 (± 29.7) | -37.5 (± 29.51) |

| | | | | |
|------------------------------------|-----------------|---------------|---------------|-----------------|
| TLC, n=101, 103, 105, 105, 104, 52 | -49.8 (± 31.78) | -43 (± 42.24) | -56 (± 34.99) | -56.3 (± 35.42) |
|------------------------------------|-----------------|---------------|---------------|-----------------|

Notes:

[1] - Intent-to-treat (ITT) Analysis Set: all randomized participants who received study product and reach

[2] - Intent-to-treat (ITT) Analysis Set: all randomized participants who received study product and reach

[3] - Intent-to-treat (ITT) Analysis Set: all randomized participants who received study product and reach

[4] - Intent-to-treat (ITT) Analysis Set: all randomized participants who received study product and reach

| End point values | Vehicle gel + Tazarotene | Vehicle gel + vehicle cream | | |
|--------------------------------------|--------------------------|-----------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 106 ^[5] | 55 ^[6] | | |
| Units: Lesion count | | | | |
| arithmetic mean (standard deviation) | | | | |
| ILC, n=101, 103, 105, 105, 104, 52 | -14.5 (± 12.76) | -8.96 (± 12.63) | | |
| NILC, n=101, 103, 105, 105, 104, 52 | -33 (± 25.89) | -18.9 (± 28.41) | | |
| TLC, n=101, 103, 105, 105, 104, 52 | -47.6 (± 33.32) | -27.8 (± 35.06) | | |

Notes:

[5] - Intent-to-treat (ITT) Analysis Set: all randomized participants who received study product and reach

[6] - Intent-to-treat (ITT) Analysis Set: all randomized participants who received study product and reach

Statistical analyses

| Statistical analysis title | Statistical analysis 1 |
|---|---|
| Comparison groups | Benzoyl peroxide gel + Tazarotene v Benzoyl peroxide/Clindamycin + Tazarotene |
| Number of subjects included in analysis | 213 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.692 ^[7] |
| Method | ANCOVA |

Notes:

[7] - For ILC

| Statistical analysis title | Statistical analysis 2 |
|---|---|
| Comparison groups | Benzoyl peroxide/Clindamycin + Tazarotene v Benzoyl peroxide gel + Tazarotene |
| Number of subjects included in analysis | 213 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.467 ^[8] |
| Method | ANCOVA |

Notes:

[8] - For ILC

| Statistical analysis title | Statistical analysis 3 |
|-----------------------------------|---|
| Comparison groups | Benzoyl peroxide/Clindamycin + Tazarotene v Clindamycin gel |

| | |
|---|------------------------|
| | + Tazarotene |
| Number of subjects included in analysis | 213 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.281 ^[9] |
| Method | ANCOVA |

Notes:

[9] - For ILC

| | |
|---|--|
| Statistical analysis title | Statistical analysis 4 |
| Comparison groups | Benzoyl peroxide/Clindamycin + Tazarotene v Vehicle gel + Tazarotene |
| Number of subjects included in analysis | 212 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.075 ^[10] |
| Method | ANCOVA |

Notes:

[10] - For ILC

| | |
|---|---|
| Statistical analysis title | Statistical analysis 5 |
| Comparison groups | Benzoyl peroxide/Clindamycin + Tazarotene v Vehicle gel + vehicle cream |
| Number of subjects included in analysis | 161 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 ^[11] |
| Method | ANCOVA |

Notes:

[11] - For ILC

| | |
|---|--|
| Statistical analysis title | Statistical analysis 6 |
| Comparison groups | Benzoyl peroxide/Clindamycin + Tazarotene v Benzoyl peroxide/Clindamycin + vehicle cream |
| Number of subjects included in analysis | 211 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 ^[12] |
| Method | ANCOVA |

Notes:

[12] - For NILC

| | |
|-----------------------------------|---|
| Statistical analysis title | Statistical analysis 7 |
| Comparison groups | Benzoyl peroxide/Clindamycin + Tazarotene v Benzoyl peroxide gel + Tazarotene |

| | |
|---|-------------------------|
| Number of subjects included in analysis | 213 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.803 ^[13] |
| Method | ANCOVA |

Notes:

[13] - For NILC

| | |
|---|--|
| Statistical analysis title | Statistical analysis 8 |
| Comparison groups | Benzoyl peroxide/Clindamycin + Tazarotene v Clindamycin gel + Tazarotene |
| Number of subjects included in analysis | 213 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.175 ^[14] |
| Method | ANCOVA |

Notes:

[14] - For NILC

| | |
|---|--|
| Statistical analysis title | Statistical analysis 9 |
| Comparison groups | Benzoyl peroxide/Clindamycin + Tazarotene v Vehicle gel + Tazarotene |
| Number of subjects included in analysis | 212 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.552 ^[15] |
| Method | ANCOVA |

Notes:

[15] - For NILC

| | |
|---|---|
| Statistical analysis title | Statistical analysis 10 |
| Comparison groups | Benzoyl peroxide/Clindamycin + Tazarotene v Vehicle gel + vehicle cream |
| Number of subjects included in analysis | 161 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 ^[16] |
| Method | ANCOVA |

Notes:

[16] - For NILC

| | |
|-----------------------------------|--|
| Statistical analysis title | Statistical analysis 11 |
| Comparison groups | Benzoyl peroxide/Clindamycin + Tazarotene v Benzoyl peroxide/Clindamycin + vehicle cream |

| | |
|---|-------------------------|
| Number of subjects included in analysis | 211 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.006 ^[17] |
| Method | ANCOVA |

Notes:

[17] - For TC

| | |
|---|---|
| Statistical analysis title | Statistical analysis 12 |
| Comparison groups | Benzoyl peroxide/Clindamycin + Tazarotene v Benzoyl peroxide gel + Tazarotene |
| Number of subjects included in analysis | 213 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.618 ^[18] |
| Method | ANCOVA |

Notes:

[18] - For TC

| | |
|---|--|
| Statistical analysis title | Statistical analysis 13 |
| Comparison groups | Benzoyl peroxide/Clindamycin + Tazarotene v Clindamycin gel + Tazarotene |
| Number of subjects included in analysis | 213 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.149 ^[19] |
| Method | ANCOVA |

Notes:

[19] - For TC

| | |
|---|--|
| Statistical analysis title | Statistical analysis 14 |
| Comparison groups | Benzoyl peroxide/Clindamycin + Tazarotene v Vehicle gel + Tazarotene |
| Number of subjects included in analysis | 212 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.255 ^[20] |
| Method | ANCOVA |

Notes:

[20] - For TC

| | |
|-----------------------------------|---|
| Statistical analysis title | Statistical analysis 15 |
| Comparison groups | Benzoyl peroxide/Clindamycin + Tazarotene v Vehicle gel + vehicle cream |

| | |
|---|---------------|
| Number of subjects included in analysis | 161 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 [21] |
| Method | ANCOVA |

Notes:

[21] - For TC

Primary: Proportion of participants with a minimum 2-grade improvement in the Investigator's Static Global Assessment (ISGA) score from Baseline to Week 12

| | |
|-----------------|--|
| End point title | Proportion of participants with a minimum 2-grade improvement in the Investigator's Static Global Assessment (ISGA) score from Baseline to Week 12 |
|-----------------|--|

End point description:

An ISGA was obtained at Baseline and at Weeks 2, 4, 8, and 12. The area considered for the ISGA was confined to the face. When possible, the same efficacy assessor performed all ISGA assessments on the same participant at all visits. Day 1 (Visit 1) was defined as Baseline. Only participants available at specified timepoints were analyzed.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Baseline and up to Week 12

| End point values | Benzoyl peroxide/Clindamycin + Tazarotene | Benzoyl peroxide/Clindamycin + vehicle cream | Benzoyl peroxide gel + Tazarotene | Clindamycin gel + Tazarotene |
|-----------------------------------|---|--|-----------------------------------|------------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 106 ^[22] | 105 ^[23] | 107 ^[24] | 108 ^[25] |
| Units: Proportion of participants | 22 | 22 | 31 | 36 |

Notes:

[22] - ITT Analysis Set

[23] - ITT Analysis Set

[24] - ITT Analysis Set

[25] - ITT Analysis Set

| End point values | Vehicle gel + Tazarotene | Vehicle gel + vehicle cream | | |
|-----------------------------------|--------------------------|-----------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 106 ^[26] | 55 ^[27] | | |
| Units: Proportion of participants | 20 | 5 | | |

Notes:

[26] - ITT Analysis Set

[27] - ITT Analysis Set

Statistical analyses

| | |
|-----------------------------------|--|
| Statistical analysis title | Statistical analysis 1 |
| Comparison groups | Benzoyl peroxide/Clindamycin + Tazarotene v Benzoyl peroxide/Clindamycin + vehicle cream |

| | |
|---|-------------------------|
| Number of subjects included in analysis | 211 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.922 |
| Method | Cochran-Mantel-Haenszel |

| | |
|---|---|
| Statistical analysis title | Statistical analysis 2 |
| Comparison groups | Benzoyl peroxide/Clindamycin + Tazarotene v Benzoyl peroxide gel + Tazarotene |
| Number of subjects included in analysis | 213 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.132 |
| Method | Cochran-Mantel-Haenszel |

| | |
|---|--|
| Statistical analysis title | Statistical analysis 3 |
| Comparison groups | Benzoyl peroxide/Clindamycin + Tazarotene v Clindamycin gel + Tazarotene |
| Number of subjects included in analysis | 214 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.02 |
| Method | Cochran-Mantel-Haenszel |

| | |
|---|--|
| Statistical analysis title | Statistical analysis 4 |
| Comparison groups | Benzoyl peroxide/Clindamycin + Tazarotene v Vehicle gel + Tazarotene |
| Number of subjects included in analysis | 212 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.706 |
| Method | Cochran-Mantel-Haenszel |

| | |
|-----------------------------------|---|
| Statistical analysis title | Statistical analysis 5 |
| Comparison groups | Benzoyl peroxide/Clindamycin + Tazarotene v Vehicle gel + vehicle cream |

| | |
|---|-------------------------|
| Number of subjects included in analysis | 161 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.009 |
| Method | Cochran-Mantel-Haenszel |

Secondary: Percent change from Baseline to Week 12 in each of 3 lesion counts (total, inflammatory, and non-inflammatory)

| | |
|-----------------|--|
| End point title | Percent change from Baseline to Week 12 in each of 3 lesion counts (total, inflammatory, and non-inflammatory) |
|-----------------|--|

End point description:

The investigator or designee took count of inflammatory lesions (papules, pustules, nodules and cysts) (ILC), noninflammatory lesions (open and closed comedones) (NILC) and total lesions (TLC) at Baseline, Weeks 2, 4, 8, and 12. Lesion counts were confined to the face. Each of 3 lesion counts (total, inflammatory and non-inflammatory) was analyzed using an analysis of covariance (ANCOVA) model with terms for treatment, center, Baseline value and treatment-by-center interaction. If the interaction was not significant at 0.1 level, this interaction was excluded in ANCOVA model. Day 1 (Visit 1) was defined as Baseline. Only participants available at specified timepoints were analyzed (represented by n=X in the category titles).

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline and up to Week 12

| End point values | Benzoyl peroxide/Clindamycin + Tazarotene | Benzoyl peroxide/Clindamycin + vehicle cream | Benzoyl peroxide gel + Tazarotene | Clindamycin gel + Tazarotene |
|--------------------------------------|---|--|-----------------------------------|------------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 106 ^[28] | 105 ^[29] | 107 ^[30] | 108 ^[31] |
| Units: Percent change | | | | |
| arithmetic mean (standard deviation) | | | | |
| ILC, n=101, 103, 105, 105, 104, 52 | -58.3 (± 45.57) | -62.4 (± 39.33) | -62.4 (± 34.83) | -65.7 (± 33.38) |
| NILC, n=101, 103, 105, 105, 104, 52 | -58 (± 29.97) | -39.2 (± 51.29) | -60.6 (± 35) | -61.2 (± 31.6) |
| TLC, n=101, 103, 105, 105, 104, 52 | -59.1 (± 29.96) | -47.9 (± 38.89) | -62 (± 29.42) | -63.4 (± 28.75) |

Notes:

[28] - ITT Analysis Set

[29] - ITT Analysis Set

[30] - ITT Analysis Set

[31] - ITT Analysis Set

| End point values | Vehicle gel + Tazarotene | Vehicle gel + vehicle cream | | |
|--------------------------------------|--------------------------|-----------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 106 ^[32] | 55 ^[33] | | |
| Units: Percent change | | | | |
| arithmetic mean (standard deviation) | | | | |
| ILC, n=101, 103, 105, 105, 104, 52 | -49 (± 40.9) | -33.5 (± 41.1) | | |

| | | | | |
|-------------------------------------|-----------------|-----------------|--|--|
| NILC, n=101, 103, 105, 105, 104, 52 | -53.1 (± 30.56) | -29.5 (± 44.05) | | |
| TLC, n=101, 103, 105, 105, 104, 52 | -51.8 (± 29.18) | -31.5 (± 37.59) | | |

Notes:

[32] - ITT Analysis Set

[33] - ITT Analysis Set

Statistical analyses

| | |
|---|--|
| Statistical analysis title | Statistical analysis 1 |
| Comparison groups | Benzoyl peroxide/Clindamycin + Tazarotene v Benzoyl peroxide/Clindamycin + vehicle cream |
| Number of subjects included in analysis | 211 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.504 [34] |
| Method | ANCOVA |

Notes:

[34] - For ILC

| | |
|---|---|
| Statistical analysis title | Statistical analysis 2 |
| Comparison groups | Benzoyl peroxide/Clindamycin + Tazarotene v Benzoyl peroxide gel + Tazarotene |
| Number of subjects included in analysis | 213 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.504 [35] |
| Method | ANCOVA |

Notes:

[35] - For ILC

| | |
|---|--|
| Statistical analysis title | Statistical analysis 3 |
| Comparison groups | Benzoyl peroxide/Clindamycin + Tazarotene v Clindamycin gel + Tazarotene |
| Number of subjects included in analysis | 214 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.177 [36] |
| Method | ANCOVA |

Notes:

[36] - For ILC

| | |
|-----------------------------------|--|
| Statistical analysis title | Statistical analysis 4 |
| Comparison groups | Benzoyl peroxide/Clindamycin + Tazarotene v Vehicle gel + Tazarotene |

| | |
|---|-------------------------|
| Number of subjects included in analysis | 212 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.084 ^[37] |
| Method | ANCOVA |

Notes:

[37] - For ILC

| | |
|---|---|
| Statistical analysis title | Statistical analysis 5 |
| Comparison groups | Benzoyl peroxide/Clindamycin + Tazarotene v Vehicle gel + vehicle cream |
| Number of subjects included in analysis | 161 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 ^[38] |
| Method | ANCOVA |

Notes:

[38] - For ILC

| | |
|---|--|
| Statistical analysis title | Statistical analysis 6 |
| Comparison groups | Benzoyl peroxide/Clindamycin + Tazarotene v Benzoyl peroxide/Clindamycin + vehicle cream |
| Number of subjects included in analysis | 211 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 ^[39] |
| Method | ANCOVA |

Notes:

[39] - For NILC

| | |
|---|---|
| Statistical analysis title | Statistical analysis 7 |
| Comparison groups | Benzoyl peroxide/Clindamycin + Tazarotene v Benzoyl peroxide gel + Tazarotene |
| Number of subjects included in analysis | 213 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.776 ^[40] |
| Method | ANCOVA |

Notes:

[40] - For NILC

| | |
|-----------------------------------|--|
| Statistical analysis title | Statistical analysis 8 |
| Comparison groups | Benzoyl peroxide/Clindamycin + Tazarotene v Clindamycin gel + Tazarotene |

| | |
|---|-------------------------|
| Number of subjects included in analysis | 214 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.465 ^[41] |
| Method | ANCOVA |

Notes:

[41] - For NILC

| | |
|---|--|
| Statistical analysis title | Statistical analysis 9 |
| Comparison groups | Benzoyl peroxide/Clindamycin + Tazarotene v Vehicle gel + Tazarotene |
| Number of subjects included in analysis | 212 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.288 ^[42] |
| Method | ANCOVA |

Notes:

[42] - For NILC

| | |
|---|---|
| Statistical analysis title | Statistical analysis 10 |
| Comparison groups | Benzoyl peroxide/Clindamycin + Tazarotene v Vehicle gel + vehicle cream |
| Number of subjects included in analysis | 161 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 ^[43] |
| Method | ANCOVA |

Notes:

[43] - For NILC

| | |
|---|--|
| Statistical analysis title | Statistical analysis 11 |
| Comparison groups | Benzoyl peroxide/Clindamycin + Tazarotene v Benzoyl peroxide/Clindamycin + vehicle cream |
| Number of subjects included in analysis | 211 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.006 ^[44] |
| Method | ANCOVA |

Notes:

[44] - For TC

| | |
|-----------------------------------|---|
| Statistical analysis title | Statistical analysis 12 |
| Comparison groups | Benzoyl peroxide/Clindamycin + Tazarotene v Benzoyl peroxide gel + Tazarotene |

| | |
|---|---------------|
| Number of subjects included in analysis | 213 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.62 [45] |
| Method | ANCOVA |

Notes:

[45] - For TC

| | |
|---|--|
| Statistical analysis title | Statistical analysis 13 |
| Comparison groups | Benzoyl peroxide/Clindamycin + Tazarotene v Clindamycin gel + Tazarotene |
| Number of subjects included in analysis | 214 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.291 [46] |
| Method | ANCOVA |

Notes:

[46] - For TC

| | |
|---|--|
| Statistical analysis title | Statistical analysis 14 |
| Comparison groups | Benzoyl peroxide/Clindamycin + Tazarotene v Vehicle gel + Tazarotene |
| Number of subjects included in analysis | 212 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.085 [47] |
| Method | ANCOVA |

Notes:

[47] - For TC

| | |
|---|---|
| Statistical analysis title | Statistical analysis 15 |
| Comparison groups | Benzoyl peroxide/Clindamycin + Tazarotene v Vehicle gel + vehicle cream |
| Number of subjects included in analysis | 161 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | < 0.001 [48] |
| Method | ANCOVA |

Notes:

[48] - For TC

Secondary: Proportion of Participants with an ISGA score of 0 or 1 at Week 12

| | |
|-----------------|--|
| End point title | Proportion of Participants with an ISGA score of 0 or 1 at Week 12 |
|-----------------|--|

End point description:

An ISGA was obtained at Baseline and at Weeks 2, 4, 8, and 12. The area considered for the ISGA was confined to the face. When possible, the same efficacy assessor performed all ISGA assessments on the same participant at all visits. Day 1 (Visit 1) was defined as Baseline. Only participants available at specified timepoints were analyzed.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 12

| End point values | Benzoyl peroxide/Clindamycin + Tazarotene | Benzoyl peroxide/Clindamycin + vehicle cream | Benzoyl peroxide gel + Tazarotene | Clindamycin gel + Tazarotene |
|-----------------------------------|---|--|-----------------------------------|------------------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 106 ^[49] | 105 ^[50] | 107 ^[51] | 108 ^[52] |
| Units: Proportion of participants | 33 | 31 | 27 | 39 |

Notes:

[49] - ITT Analysis Set

[50] - ITT Analysis Set

[51] - ITT Analysis Set

[52] - ITT Analysis Set

| End point values | Vehicle gel + Tazarotene | Vehicle gel + vehicle cream | | |
|-----------------------------------|--------------------------|-----------------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 106 ^[53] | 55 ^[54] | | |
| Units: Proportion of participants | 22 | 13 | | |

Notes:

[53] - ITT Analysis Set

[54] - ITT Analysis Set

Statistical analyses

| | |
|---|--|
| Statistical analysis title | Statistical analysis 1 |
| Comparison groups | Benzoyl peroxide/Clindamycin + Tazarotene v Benzoyl peroxide/Clindamycin + vehicle cream |
| Number of subjects included in analysis | 211 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.652 |
| Method | Cochran-Mantel-Haenszel |

| | |
|---|---|
| Statistical analysis title | Statistical analysis 2 |
| Comparison groups | Benzoyl peroxide/Clindamycin + Tazarotene v Benzoyl peroxide gel + Tazarotene |
| Number of subjects included in analysis | 213 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.279 |
| Method | Cochran-Mantel-Haenszel |

| | |
|-----------------------------------|------------------------|
| Statistical analysis title | Statistical analysis 3 |
|-----------------------------------|------------------------|

| | |
|---|--|
| Comparison groups | Benzoyl peroxide/Clindamycin + Tazarotene v Clindamycin gel + Tazarotene |
| Number of subjects included in analysis | 214 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.312 |
| Method | Cochran-Mantel-Haenszel |

| | |
|---|--|
| Statistical analysis title | Statistical analysis 4 |
| Comparison groups | Benzoyl peroxide/Clindamycin + Tazarotene v Vehicle gel + Tazarotene |
| Number of subjects included in analysis | 212 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.063 |
| Method | Cochran-Mantel-Haenszel |

| | |
|---|---|
| Statistical analysis title | Statistical analysis 5 |
| Comparison groups | Benzoyl peroxide/Clindamycin + Tazarotene v Vehicle gel + vehicle cream |
| Number of subjects included in analysis | 161 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.005 |
| Method | Cochran-Mantel-Haenszel |

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from Day 1 up to Day 89.

Adverse event reporting additional description:

SAEs and non-serious AEs were assessed in the ITT Analysis Set.

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|------|
| Dictionary version | 10.1 |
|--------------------|------|

Reporting groups

| | |
|-----------------------|---|
| Reporting group title | Benzoyl peroxide/Clindamycin + Tazarotene |
|-----------------------|---|

Reporting group description:

Participants applied the study product (Benzoyl peroxide/Clindamycin + Tazarotene) to the face once daily in the evening up to 12 weeks. Two actuations of test product (approximately 0.6 grams [g] of the combined product in an approximate 1:1 ratio) were dispensed into the participant's palm and mixed. A thin film was then applied to the entire face.

| | |
|-----------------------|--|
| Reporting group title | Benzoyl peroxide/Clindamycin + vehicle cream |
|-----------------------|--|

Reporting group description:

Participants applied the study product (Benzoyl peroxide/Clindamycin + vehicle cream with identical ingredients as Tazarotene) to the face once daily in the evening up to 12 weeks. Two actuations of test product (approximately 0.6 g of the combined product in an approximate 1:1 ratio) were dispensed into the participant's palm and mixed. A thin film was then applied to the entire face.

| | |
|-----------------------|-----------------------------------|
| Reporting group title | Benzoyl peroxide gel + Tazarotene |
|-----------------------|-----------------------------------|

Reporting group description:

Participants applied the study product (Benzoyl peroxide gel + Tazarotene) to the face once daily in the evening up to 12 weeks. Two actuations of test product (approximately 0.6 g of the combined product in an approximate 1:1 ratio) were dispensed into the participant's palm and mixed. A thin film was then applied to the entire face.

| | |
|-----------------------|------------------------------|
| Reporting group title | Clindamycin gel + Tazarotene |
|-----------------------|------------------------------|

Reporting group description:

Participants applied the study product (Clindamycin gel + Tazarotene) to the face once daily in the evening up to 12 weeks. Two actuations of test product (approximately 0.6 g of the combined product in an approximate 1:1 ratio) were dispensed into the participant's palm and mixed. A thin film was then applied to the entire face.

| | |
|-----------------------|--------------------------|
| Reporting group title | Vehicle gel + Tazarotene |
|-----------------------|--------------------------|

Reporting group description:

Participants applied the study product (Vehicle gel with identical ingredients as Benzoyl peroxide/Clindamycin + Tazarotene) to the face once daily in the evening up to 12 weeks. Two actuations of test product (approximately 0.6 g of the combined product in an approximate 1:1 ratio) were dispensed into the participant's palm and mixed. A thin film was then applied to the entire face.

| | |
|-----------------------|-----------------------------|
| Reporting group title | Vehicle gel + vehicle cream |
|-----------------------|-----------------------------|

Reporting group description:

Participants applied the study product (Vehicle gel with identical ingredients as Benzoyl peroxide/Clindamycin+ vehicle cream with identical ingredients as Tazarotene) to the face once daily in the evening up to 12 weeks. Two actuations of test product (approximately 0.6 g of the combined product in an approximate 1:1 ratio) were dispensed into the participant's palm and mixed. A thin film was then applied to the entire face.

| Serious adverse events | Benzoyl peroxide/Clindamycin + Tazarotene | Benzoyl peroxide/Clindamycin + vehicle cream | Benzoyl peroxide gel + Tazarotene |
|---|---|--|-----------------------------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 105 (0.00%) | 0 / 107 (0.00%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | | | |

| Serious adverse events | Clindamycin gel + Tazarotene | Vehicle gel + Tazarotene | Vehicle gel + vehicle cream |
|---|------------------------------|--------------------------|-----------------------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 0 / 108 (0.00%) | 0 / 106 (0.00%) | 0 / 55 (0.00%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | | | |

Frequency threshold for reporting non-serious adverse events: 0 %

| Non-serious adverse events | Benzoyl peroxide/Clindamycin + Tazarotene | Benzoyl peroxide/Clindamycin + vehicle cream | Benzoyl peroxide gel + Tazarotene |
|---|---|--|-----------------------------------|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 25 / 106 (23.58%) | 22 / 105 (20.95%) | 24 / 107 (22.43%) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Fibromatosis | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 105 (0.00%) | 0 / 107 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vascular disorders | | | |
| Hypotension | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 1 / 105 (0.95%) | 1 / 107 (0.93%) |
| occurrences (all) | 0 | 1 | 1 |
| Surgical and medical procedures | | | |
| Wisdom teeth removal | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 1 / 105 (0.95%) | 0 / 107 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| General disorders and administration site conditions | | | |
| Application site burn | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 105 (0.00%) | 1 / 107 (0.93%) |
| occurrences (all) | 0 | 0 | 1 |
| Application site dermatitis | | | |

| | | | |
|---|----------------------|----------------------|----------------------|
| subjects affected / exposed occurrences (all) | 0 / 106 (0.00%) 0 | 0 / 105 (0.00%) 0 | 0 / 107 (0.00%) 0 |
| Application site discolouration subjects affected / exposed occurrences (all) | 1 / 106 (0.94%) 1 | 0 / 105 (0.00%) 0 | 0 / 107 (0.00%) 0 |
| Application site dryness subjects affected / exposed occurrences (all) | 1 / 106 (0.94%) 1 | 0 / 105 (0.00%) 0 | 1 / 107 (0.93%) 1 |
| Application site erythema subjects affected / exposed occurrences (all) | 1 / 106 (0.94%) 1 | 0 / 105 (0.00%) 0 | 2 / 107 (1.87%) 2 |
| Application site exfoliation subjects affected / exposed occurrences (all) | 0 / 106 (0.00%) 0 | 0 / 105 (0.00%) 0 | 1 / 107 (0.93%) 1 |
| Application site irritation subjects affected / exposed occurrences (all) | 1 / 106 (0.94%) 1 | 0 / 105 (0.00%) 0 | 3 / 107 (2.80%) 3 |
| Application site pain subjects affected / exposed occurrences (all) | 0 / 106 (0.00%) 0 | 0 / 105 (0.00%) 0 | 2 / 107 (1.87%) 2 |
| Application site pruritus subjects affected / exposed occurrences (all) | 0 / 106 (0.00%) 0 | 0 / 105 (0.00%) 0 | 0 / 107 (0.00%) 0 |
| Condition aggravated subjects affected / exposed occurrences (all) | 0 / 106 (0.00%) 0 | 0 / 105 (0.00%) 0 | 0 / 107 (0.00%) 0 |
| Cyst subjects affected / exposed occurrences (all) | 0 / 106 (0.00%) 0 | 1 / 105 (0.95%) 1 | 0 / 107 (0.00%) 0 |
| Local swelling subjects affected / exposed occurrences (all) | 0 / 106 (0.00%) 0 | 0 / 105 (0.00%) 0 | 0 / 107 (0.00%) 0 |
| Pain subjects affected / exposed occurrences (all) | 0 / 106 (0.00%) 0 | 0 / 105 (0.00%) 0 | 0 / 107 (0.00%) 0 |
| Pyrexia | | | |

| | | | |
|---|----------------------|----------------------|----------------------|
| subjects affected / exposed occurrences (all) | 0 / 106 (0.00%) 0 | 0 / 105 (0.00%) 0 | 0 / 107 (0.00%) 0 |
| Immune system disorders | | | |
| Allergy to arthropod bite subjects affected / exposed occurrences (all) | 2 / 106 (1.89%) 2 | 0 / 105 (0.00%) 0 | 0 / 107 (0.00%) 0 |
| Allergy to metals subjects affected / exposed occurrences (all) | 0 / 106 (0.00%) 0 | 0 / 105 (0.00%) 0 | 0 / 107 (0.00%) 0 |
| Food allergy subjects affected / exposed occurrences (all) | 0 / 106 (0.00%) 0 | 1 / 105 (0.95%) 1 | 0 / 107 (0.00%) 0 |
| Multiple allergies subjects affected / exposed occurrences (all) | 0 / 106 (0.00%) 0 | 0 / 105 (0.00%) 0 | 1 / 107 (0.93%) 1 |
| Seasonal allergy subjects affected / exposed occurrences (all) | 0 / 106 (0.00%) 0 | 0 / 105 (0.00%) 0 | 1 / 107 (0.93%) 1 |
| Reproductive system and breast disorders | | | |
| Menorrhagia subjects affected / exposed occurrences (all) | 1 / 106 (0.94%) 1 | 0 / 105 (0.00%) 0 | 0 / 107 (0.00%) 0 |
| Ovarian cyst subjects affected / exposed occurrences (all) | 1 / 106 (0.94%) 1 | 0 / 105 (0.00%) 0 | 0 / 107 (0.00%) 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Bronchitis subjects affected / exposed occurrences (all) | 1 / 106 (0.94%) 1 | 0 / 105 (0.00%) 0 | 0 / 107 (0.00%) 0 |
| Cough subjects affected / exposed occurrences (all) | 0 / 106 (0.00%) 0 | 0 / 105 (0.00%) 0 | 1 / 107 (0.93%) 1 |
| Epistaxis subjects affected / exposed occurrences (all) | 0 / 106 (0.00%) 0 | 0 / 105 (0.00%) 0 | 3 / 107 (2.80%) 3 |
| Nasal congestion | | | |

| | | | |
|--|----------------------|----------------------|----------------------|
| subjects affected / exposed occurrences (all) | 0 / 106 (0.00%) 0 | 0 / 105 (0.00%) 0 | 0 / 107 (0.00%) 0 |
| Pharyngolaryngeal pain subjects affected / exposed occurrences (all) | 0 / 106 (0.00%) 0 | 0 / 105 (0.00%) 0 | 1 / 107 (0.93%) 1 |
| Rhinorrhoea subjects affected / exposed occurrences (all) | 0 / 106 (0.00%) 0 | 1 / 105 (0.95%) 1 | 0 / 107 (0.00%) 0 |
| Sinus congestion subjects affected / exposed occurrences (all) | 0 / 106 (0.00%) 0 | 1 / 105 (0.95%) 1 | 0 / 107 (0.00%) 0 |
| Investigations | | | |
| Smear cervix abnormal subjects affected / exposed occurrences (all) | 0 / 106 (0.00%) 0 | 0 / 105 (0.00%) 0 | 0 / 107 (0.00%) 0 |
| Injury, poisoning and procedural complications | | | |
| Contusion subjects affected / exposed occurrences (all) | 0 / 106 (0.00%) 0 | 0 / 105 (0.00%) 0 | 0 / 107 (0.00%) 0 |
| Excoriation subjects affected / exposed occurrences (all) | 0 / 106 (0.00%) 0 | 1 / 105 (0.95%) 1 | 1 / 107 (0.93%) 1 |
| Facial bones fracture subjects affected / exposed occurrences (all) | 0 / 106 (0.00%) 0 | 1 / 105 (0.95%) 1 | 0 / 107 (0.00%) 0 |
| Joint injury subjects affected / exposed occurrences (all) | 0 / 106 (0.00%) 0 | 0 / 105 (0.00%) 0 | 0 / 107 (0.00%) 0 |
| Joint sprain subjects affected / exposed occurrences (all) | 1 / 106 (0.94%) 1 | 0 / 105 (0.00%) 0 | 0 / 107 (0.00%) 0 |
| Muscle strain subjects affected / exposed occurrences (all) | 1 / 106 (0.94%) 1 | 0 / 105 (0.00%) 0 | 0 / 107 (0.00%) 0 |
| Procedural pain | | | |

| | | | |
|---|----------------------|----------------------|----------------------|
| subjects affected / exposed occurrences (all) | 1 / 106 (0.94%) 1 | 1 / 105 (0.95%) 1 | 0 / 107 (0.00%) 0 |
| Sunburn subjects affected / exposed occurrences (all) | 0 / 106 (0.00%) 0 | 1 / 105 (0.95%) 1 | 0 / 107 (0.00%) 0 |
| Nervous system disorders Headache subjects affected / exposed occurrences (all) | 0 / 106 (0.00%) 0 | 0 / 105 (0.00%) 0 | 1 / 107 (0.93%) 1 |
| Insomnia subjects affected / exposed occurrences (all) | 0 / 106 (0.00%) 0 | 0 / 105 (0.00%) 0 | 1 / 107 (0.93%) 1 |
| Eye disorders Conjunctivitis subjects affected / exposed occurrences (all) | 1 / 106 (0.94%) 1 | 0 / 105 (0.00%) 0 | 0 / 107 (0.00%) 0 |
| Gastrointestinal disorders Aphthous stomatitis subjects affected / exposed occurrences (all) | 0 / 106 (0.00%) 0 | 1 / 105 (0.95%) 1 | 0 / 107 (0.00%) 0 |
| Dyspepsia subjects affected / exposed occurrences (all) | 0 / 106 (0.00%) 0 | 0 / 105 (0.00%) 0 | 0 / 107 (0.00%) 0 |
| Lip blister subjects affected / exposed occurrences (all) | 1 / 106 (0.94%) 1 | 0 / 105 (0.00%) 0 | 0 / 107 (0.00%) 0 |
| Nausea subjects affected / exposed occurrences (all) | 0 / 106 (0.00%) 0 | 0 / 105 (0.00%) 0 | 0 / 107 (0.00%) 0 |
| Tooth impacted subjects affected / exposed occurrences (all) | 1 / 106 (0.94%) 1 | 0 / 105 (0.00%) 0 | 0 / 107 (0.00%) 0 |
| Vomiting subjects affected / exposed occurrences (all) | 1 / 106 (0.94%) 1 | 0 / 105 (0.00%) 0 | 0 / 107 (0.00%) 0 |
| Skin and subcutaneous tissue disorders | | | |

| | | | |
|---|----------------------|----------------------|----------------------|
| Dermatitis subjects affected / exposed occurrences (all) | 1 / 106 (0.94%) 1 | 0 / 105 (0.00%) 0 | 1 / 107 (0.93%) 1 |
| Dermatitis atopic subjects affected / exposed occurrences (all) | 0 / 106 (0.00%) 0 | 0 / 105 (0.00%) 0 | 0 / 107 (0.00%) 0 |
| Dry skin subjects affected / exposed occurrences (all) | 0 / 106 (0.00%) 0 | 0 / 105 (0.00%) 0 | 0 / 107 (0.00%) 0 |
| Erythema subjects affected / exposed occurrences (all) | 1 / 106 (0.94%) 1 | 0 / 105 (0.00%) 0 | 0 / 107 (0.00%) 0 |
| Rash generalised subjects affected / exposed occurrences (all) | 0 / 106 (0.00%) 0 | 1 / 105 (0.95%) 1 | 0 / 107 (0.00%) 0 |
| Skin exfoliation subjects affected / exposed occurrences (all) | 0 / 106 (0.00%) 0 | 0 / 105 (0.00%) 0 | 0 / 107 (0.00%) 0 |
| Skin irritation subjects affected / exposed occurrences (all) | 0 / 106 (0.00%) 0 | 0 / 105 (0.00%) 0 | 0 / 107 (0.00%) 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia subjects affected / exposed occurrences (all) | 0 / 106 (0.00%) 0 | 0 / 105 (0.00%) 0 | 0 / 107 (0.00%) 0 |
| Back pain subjects affected / exposed occurrences (all) | 0 / 106 (0.00%) 0 | 1 / 105 (0.95%) 1 | 0 / 107 (0.00%) 0 |
| Infections and infestations | | | |
| Cellulitis subjects affected / exposed occurrences (all) | 0 / 106 (0.00%) 0 | 1 / 105 (0.95%) 1 | 0 / 107 (0.00%) 0 |
| Ear infection subjects affected / exposed occurrences (all) | 0 / 106 (0.00%) 0 | 0 / 105 (0.00%) 0 | 1 / 107 (0.93%) 1 |
| Furuncle | | | |

| | | | |
|-----------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 105 (0.00%) | 1 / 107 (0.93%) |
| occurrences (all) | 0 | 0 | 1 |
| Gastroenteritis | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 105 (0.00%) | 1 / 107 (0.93%) |
| occurrences (all) | 0 | 0 | 1 |
| Gastroenteritis viral | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 1 / 105 (0.95%) | 0 / 107 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Herpes simplex | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 105 (0.00%) | 0 / 107 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hordeolum | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 105 (0.00%) | 0 / 107 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Infectious mononucleosis | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 1 / 105 (0.95%) | 1 / 107 (0.93%) |
| occurrences (all) | 0 | 1 | 1 |
| Influenza | | | |
| subjects affected / exposed | 1 / 106 (0.94%) | 0 / 105 (0.00%) | 0 / 107 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Localised infection | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 1 / 105 (0.95%) | 0 / 107 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Lyme disease | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 105 (0.00%) | 1 / 107 (0.93%) |
| occurrences (all) | 0 | 0 | 1 |
| Nasopharyngitis | | | |
| subjects affected / exposed | 3 / 106 (2.83%) | 3 / 105 (2.86%) | 3 / 107 (2.80%) |
| occurrences (all) | 3 | 3 | 3 |
| Oral herpes | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 1 / 105 (0.95%) | 0 / 107 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Pharyngitis | | | |
| subjects affected / exposed | 0 / 106 (0.00%) | 0 / 105 (0.00%) | 1 / 107 (0.93%) |
| occurrences (all) | 0 | 0 | 1 |
| Pharyngitis streptococcal | | | |

| | | | |
|---|----------------------|----------------------|----------------------|
| subjects affected / exposed occurrences (all) | 1 / 106 (0.94%) 1 | 1 / 105 (0.95%) 1 | 0 / 107 (0.00%) 0 |
| Sinusitis subjects affected / exposed occurrences (all) | 1 / 106 (0.94%) 1 | 1 / 105 (0.95%) 1 | 2 / 107 (1.87%) 2 |
| Tinea pedis subjects affected / exposed occurrences (all) | 0 / 106 (0.00%) 0 | 1 / 105 (0.95%) 1 | 0 / 107 (0.00%) 0 |
| Tonsillitis subjects affected / exposed occurrences (all) | 0 / 106 (0.00%) 0 | 0 / 105 (0.00%) 0 | 0 / 107 (0.00%) 0 |
| Upper respiratory tract infection subjects affected / exposed occurrences (all) | 5 / 106 (4.72%) 5 | 4 / 105 (3.81%) 4 | 5 / 107 (4.67%) 5 |
| Urinary tract infection subjects affected / exposed occurrences (all) | 1 / 106 (0.94%) 1 | 0 / 105 (0.00%) 0 | 1 / 107 (0.93%) 1 |
| Vaginitis bacterial subjects affected / exposed occurrences (all) | 0 / 106 (0.00%) 0 | 0 / 105 (0.00%) 0 | 0 / 107 (0.00%) 0 |
| Viral infection subjects affected / exposed occurrences (all) | 1 / 106 (0.94%) 1 | 0 / 105 (0.00%) 0 | 0 / 107 (0.00%) 0 |
| Viral pharyngitis subjects affected / exposed occurrences (all) | 0 / 106 (0.00%) 0 | 0 / 105 (0.00%) 0 | 0 / 107 (0.00%) 0 |
| Metabolism and nutrition disorders Dehydration subjects affected / exposed occurrences (all) | 1 / 106 (0.94%) 1 | 0 / 105 (0.00%) 0 | 0 / 107 (0.00%) 0 |

| Non-serious adverse events | Clindamycin gel + Tazarotene | Vehicle gel + Tazarotene | Vehicle gel + vehicle cream |
|---|---------------------------------|-----------------------------|--------------------------------|
| Total subjects affected by non-serious adverse events subjects affected / exposed | 18 / 108 (16.67%) | 29 / 106 (27.36%) | 12 / 55 (21.82%) |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |

| | | | |
|---|----------------------|----------------------|---------------------|
| Fibromatosis subjects affected / exposed occurrences (all) | 0 / 108 (0.00%) 0 | 1 / 106 (0.94%) 1 | 0 / 55 (0.00%) 0 |
| Vascular disorders Hypotension subjects affected / exposed occurrences (all) | 0 / 108 (0.00%) 0 | 0 / 106 (0.00%) 0 | 0 / 55 (0.00%) 0 |
| Surgical and medical procedures Wisdom teeth removal subjects affected / exposed occurrences (all) | 0 / 108 (0.00%) 0 | 0 / 106 (0.00%) 0 | 0 / 55 (0.00%) 0 |
| General disorders and administration site conditions | | | |
| Application site burn subjects affected / exposed occurrences (all) | 0 / 108 (0.00%) 0 | 1 / 106 (0.94%) 1 | 1 / 55 (1.82%) 1 |
| Application site dermatitis subjects affected / exposed occurrences (all) | 0 / 108 (0.00%) 0 | 1 / 106 (0.94%) 1 | 0 / 55 (0.00%) 0 |
| Application site discolouration subjects affected / exposed occurrences (all) | 0 / 108 (0.00%) 0 | 0 / 106 (0.00%) 0 | 0 / 55 (0.00%) 0 |
| Application site dryness subjects affected / exposed occurrences (all) | 1 / 108 (0.93%) 1 | 1 / 106 (0.94%) 1 | 1 / 55 (1.82%) 1 |
| Application site erythema subjects affected / exposed occurrences (all) | 1 / 108 (0.93%) 1 | 0 / 106 (0.00%) 0 | 1 / 55 (1.82%) 1 |
| Application site exfoliation subjects affected / exposed occurrences (all) | 0 / 108 (0.00%) 0 | 0 / 106 (0.00%) 0 | 1 / 55 (1.82%) 1 |
| Application site irritation subjects affected / exposed occurrences (all) | 4 / 108 (3.70%) 4 | 2 / 106 (1.89%) 2 | 0 / 55 (0.00%) 0 |
| Application site pain subjects affected / exposed occurrences (all) | 0 / 108 (0.00%) 0 | 0 / 106 (0.00%) 0 | 2 / 55 (3.64%) 2 |

| | | | |
|---|----------------------|----------------------|---------------------|
| Application site pruritus subjects affected / exposed occurrences (all) | 0 / 108 (0.00%) 0 | 2 / 106 (1.89%) 2 | 1 / 55 (1.82%) 1 |
| Condition aggravated subjects affected / exposed occurrences (all) | 0 / 108 (0.00%) 0 | 1 / 106 (0.94%) 1 | 0 / 55 (0.00%) 0 |
| Cyst subjects affected / exposed occurrences (all) | 1 / 108 (0.93%) 1 | 0 / 106 (0.00%) 0 | 0 / 55 (0.00%) 0 |
| Local swelling subjects affected / exposed occurrences (all) | 1 / 108 (0.93%) 1 | 0 / 106 (0.00%) 0 | 0 / 55 (0.00%) 0 |
| Pain subjects affected / exposed occurrences (all) | 1 / 108 (0.93%) 1 | 0 / 106 (0.00%) 0 | 0 / 55 (0.00%) 0 |
| Pyrexia subjects affected / exposed occurrences (all) | 1 / 108 (0.93%) 1 | 1 / 106 (0.94%) 1 | 0 / 55 (0.00%) 0 |
| Immune system disorders | | | |
| Allergy to arthropod bite subjects affected / exposed occurrences (all) | 0 / 108 (0.00%) 0 | 1 / 106 (0.94%) 1 | 0 / 55 (0.00%) 0 |
| Allergy to metals subjects affected / exposed occurrences (all) | 1 / 108 (0.93%) 1 | 0 / 106 (0.00%) 0 | 0 / 55 (0.00%) 0 |
| Food allergy subjects affected / exposed occurrences (all) | 0 / 108 (0.00%) 0 | 0 / 106 (0.00%) 0 | 0 / 55 (0.00%) 0 |
| Multiple allergies subjects affected / exposed occurrences (all) | 0 / 108 (0.00%) 0 | 0 / 106 (0.00%) 0 | 0 / 55 (0.00%) 0 |
| Seasonal allergy subjects affected / exposed occurrences (all) | 0 / 108 (0.00%) 0 | 0 / 106 (0.00%) 0 | 0 / 55 (0.00%) 0 |
| Reproductive system and breast disorders | | | |

| | | | |
|--|----------------------|----------------------|---------------------|
| Menorrhagia subjects affected / exposed occurrences (all) | 0 / 108 (0.00%) 0 | 0 / 106 (0.00%) 0 | 0 / 55 (0.00%) 0 |
| Ovarian cyst subjects affected / exposed occurrences (all) | 0 / 108 (0.00%) 0 | 0 / 106 (0.00%) 0 | 0 / 55 (0.00%) 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Bronchitis subjects affected / exposed occurrences (all) | 0 / 108 (0.00%) 0 | 0 / 106 (0.00%) 0 | 0 / 55 (0.00%) 0 |
| Cough subjects affected / exposed occurrences (all) | 0 / 108 (0.00%) 0 | 0 / 106 (0.00%) 0 | 0 / 55 (0.00%) 0 |
| Epistaxis subjects affected / exposed occurrences (all) | 0 / 108 (0.00%) 0 | 0 / 106 (0.00%) 0 | 0 / 55 (0.00%) 0 |
| Nasal congestion subjects affected / exposed occurrences (all) | 0 / 108 (0.00%) 0 | 1 / 106 (0.94%) 1 | 0 / 55 (0.00%) 0 |
| Pharyngolaryngeal pain subjects affected / exposed occurrences (all) | 0 / 108 (0.00%) 0 | 1 / 106 (0.94%) 1 | 0 / 55 (0.00%) 0 |
| Rhinorrhoea subjects affected / exposed occurrences (all) | 0 / 108 (0.00%) 0 | 0 / 106 (0.00%) 0 | 0 / 55 (0.00%) 0 |
| Sinus congestion subjects affected / exposed occurrences (all) | 0 / 108 (0.00%) 0 | 0 / 106 (0.00%) 0 | 1 / 55 (1.82%) 1 |
| Investigations | | | |
| Smear cervix abnormal subjects affected / exposed occurrences (all) | 0 / 108 (0.00%) 0 | 0 / 106 (0.00%) 0 | 1 / 55 (1.82%) 1 |
| Injury, poisoning and procedural complications | | | |
| Contusion subjects affected / exposed occurrences (all) | 1 / 108 (0.93%) 1 | 0 / 106 (0.00%) 0 | 0 / 55 (0.00%) 0 |

| | | | |
|-----------------------------|-----------------|-----------------|----------------|
| Excoriation | | | |
| subjects affected / exposed | 1 / 108 (0.93%) | 0 / 106 (0.00%) | 0 / 55 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Facial bones fracture | | | |
| subjects affected / exposed | 0 / 108 (0.00%) | 0 / 106 (0.00%) | 0 / 55 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Joint injury | | | |
| subjects affected / exposed | 0 / 108 (0.00%) | 0 / 106 (0.00%) | 1 / 55 (1.82%) |
| occurrences (all) | 0 | 0 | 1 |
| Joint sprain | | | |
| subjects affected / exposed | 0 / 108 (0.00%) | 0 / 106 (0.00%) | 0 / 55 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Muscle strain | | | |
| subjects affected / exposed | 0 / 108 (0.00%) | 0 / 106 (0.00%) | 0 / 55 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Procedural pain | | | |
| subjects affected / exposed | 1 / 108 (0.93%) | 0 / 106 (0.00%) | 0 / 55 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Sunburn | | | |
| subjects affected / exposed | 0 / 108 (0.00%) | 1 / 106 (0.94%) | 0 / 55 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Nervous system disorders | | | |
| Headache | | | |
| subjects affected / exposed | 0 / 108 (0.00%) | 2 / 106 (1.89%) | 0 / 55 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Insomnia | | | |
| subjects affected / exposed | 0 / 108 (0.00%) | 0 / 106 (0.00%) | 0 / 55 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Eye disorders | | | |
| Conjunctivitis | | | |
| subjects affected / exposed | 0 / 108 (0.00%) | 0 / 106 (0.00%) | 0 / 55 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastrointestinal disorders | | | |
| Apthous stomatitis | | | |
| subjects affected / exposed | 0 / 108 (0.00%) | 0 / 106 (0.00%) | 0 / 55 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Dyspepsia | | | |

| | | | |
|--|-----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 108 (0.00%) | 1 / 106 (0.94%) | 0 / 55 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Lip blister | | | |
| subjects affected / exposed | 0 / 108 (0.00%) | 0 / 106 (0.00%) | 0 / 55 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nausea | | | |
| subjects affected / exposed | 0 / 108 (0.00%) | 1 / 106 (0.94%) | 0 / 55 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Tooth impacted | | | |
| subjects affected / exposed | 0 / 108 (0.00%) | 0 / 106 (0.00%) | 0 / 55 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vomiting | | | |
| subjects affected / exposed | 0 / 108 (0.00%) | 0 / 106 (0.00%) | 0 / 55 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin and subcutaneous tissue disorders | | | |
| Dermatitis | | | |
| subjects affected / exposed | 0 / 108 (0.00%) | 2 / 106 (1.89%) | 0 / 55 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Dermatitis atopic | | | |
| subjects affected / exposed | 1 / 108 (0.93%) | 0 / 106 (0.00%) | 0 / 55 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Dry skin | | | |
| subjects affected / exposed | 0 / 108 (0.00%) | 1 / 106 (0.94%) | 0 / 55 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Erythema | | | |
| subjects affected / exposed | 0 / 108 (0.00%) | 0 / 106 (0.00%) | 0 / 55 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Rash generalised | | | |
| subjects affected / exposed | 0 / 108 (0.00%) | 0 / 106 (0.00%) | 0 / 55 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Skin exfoliation | | | |
| subjects affected / exposed | 0 / 108 (0.00%) | 1 / 106 (0.94%) | 0 / 55 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Skin irritation | | | |
| subjects affected / exposed | 0 / 108 (0.00%) | 1 / 106 (0.94%) | 0 / 55 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |

| | | | |
|---|-----------------|-----------------|----------------|
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 1 / 108 (0.93%) | 0 / 106 (0.00%) | 0 / 55 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Back pain | | | |
| subjects affected / exposed | 0 / 108 (0.00%) | 1 / 106 (0.94%) | 1 / 55 (1.82%) |
| occurrences (all) | 0 | 1 | 1 |
| Infections and infestations | | | |
| Cellulitis | | | |
| subjects affected / exposed | 0 / 108 (0.00%) | 0 / 106 (0.00%) | 0 / 55 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Ear infection | | | |
| subjects affected / exposed | 1 / 108 (0.93%) | 0 / 106 (0.00%) | 0 / 55 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Furuncle | | | |
| subjects affected / exposed | 0 / 108 (0.00%) | 0 / 106 (0.00%) | 0 / 55 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Gastroenteritis | | | |
| subjects affected / exposed | 1 / 108 (0.93%) | 0 / 106 (0.00%) | 0 / 55 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Gastroenteritis viral | | | |
| subjects affected / exposed | 1 / 108 (0.93%) | 0 / 106 (0.00%) | 1 / 55 (1.82%) |
| occurrences (all) | 1 | 0 | 1 |
| Herpes simplex | | | |
| subjects affected / exposed | 1 / 108 (0.93%) | 0 / 106 (0.00%) | 0 / 55 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Hordeolum | | | |
| subjects affected / exposed | 0 / 108 (0.00%) | 0 / 106 (0.00%) | 0 / 55 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Infectious mononucleosis | | | |
| subjects affected / exposed | 0 / 108 (0.00%) | 0 / 106 (0.00%) | 0 / 55 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Influenza | | | |
| subjects affected / exposed | 0 / 108 (0.00%) | 2 / 106 (1.89%) | 0 / 55 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Localised infection | | | |

| | | | |
|-----------------------------------|-----------------|-----------------|----------------|
| subjects affected / exposed | 0 / 108 (0.00%) | 0 / 106 (0.00%) | 0 / 55 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Lyme disease | | | |
| subjects affected / exposed | 0 / 108 (0.00%) | 0 / 106 (0.00%) | 0 / 55 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Nasopharyngitis | | | |
| subjects affected / exposed | 5 / 108 (4.63%) | 4 / 106 (3.77%) | 3 / 55 (5.45%) |
| occurrences (all) | 5 | 4 | 3 |
| Oral herpes | | | |
| subjects affected / exposed | 0 / 108 (0.00%) | 1 / 106 (0.94%) | 0 / 55 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Pharyngitis | | | |
| subjects affected / exposed | 0 / 108 (0.00%) | 0 / 106 (0.00%) | 1 / 55 (1.82%) |
| occurrences (all) | 0 | 0 | 1 |
| Pharyngitis streptococcal | | | |
| subjects affected / exposed | 0 / 108 (0.00%) | 0 / 106 (0.00%) | 0 / 55 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Sinusitis | | | |
| subjects affected / exposed | 0 / 108 (0.00%) | 1 / 106 (0.94%) | 2 / 55 (3.64%) |
| occurrences (all) | 0 | 1 | 2 |
| Tinea pedis | | | |
| subjects affected / exposed | 0 / 108 (0.00%) | 0 / 106 (0.00%) | 0 / 55 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Tonsillitis | | | |
| subjects affected / exposed | 1 / 108 (0.93%) | 0 / 106 (0.00%) | 0 / 55 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 2 / 108 (1.85%) | 4 / 106 (3.77%) | 1 / 55 (1.82%) |
| occurrences (all) | 2 | 4 | 1 |
| Urinary tract infection | | | |
| subjects affected / exposed | 0 / 108 (0.00%) | 0 / 106 (0.00%) | 0 / 55 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Vaginitis bacterial | | | |
| subjects affected / exposed | 1 / 108 (0.93%) | 0 / 106 (0.00%) | 0 / 55 (0.00%) |
| occurrences (all) | 1 | 0 | 0 |
| Viral infection | | | |

| | | | |
|---|----------------------|----------------------|---------------------|
| subjects affected / exposed occurrences (all) | 0 / 108 (0.00%) 0 | 0 / 106 (0.00%) 0 | 0 / 55 (0.00%) 0 |
| Viral pharyngitis subjects affected / exposed occurrences (all) | 1 / 108 (0.93%) 1 | 0 / 106 (0.00%) 0 | 0 / 55 (0.00%) 0 |
| Metabolism and nutrition disorders Dehydration subjects affected / exposed occurrences (all) | 0 / 108 (0.00%) 0 | 0 / 106 (0.00%) 0 | 0 / 55 (0.00%) 0 |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|----------------|---|
| 21 August 2008 | 21 Aug 2008 In Section 7.2, Inclusion criterion #3, was updated " To Allow up to 80 inflammatory lesions (increased from 60), and up to 3 nodules of no more than 5 millimeter (mm) each (increased from none)." In Section 7.2, Inclusion criterion #7 was removed. In Section 7.3, Exclusion criterion #3, was updated "To Allow subjects with seborrheic dermatitis if it has been inactive for at least a year and/or does not affect the face." In Section 12.1.3, "Additional endpoints were revised to include a 2-grade drop in ISGA from Baseline to weeks 2, 4, and 8." In Section 12.4.5.3, "Definition of statistical analysis to be used for the additional endpoint of the proportion of subjects with an ISGA score of 0 or 1 at weeks 2, 4, and 8 was added." |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported